EARLY TIMES REPORT
JAMMU, Dec 21: The Jammu and Kashmir government on Monday constituted UT Level and District Level Adverse Events Following Immunization (AEFI) committees.
“Sanction is hereby accorded to the constitution of Union territory Level Committee & District Level Committee(s), comprising the following for management of adverse events of the COVID-19 Vaccine, if any”, reads the order issued by General Administration Department.
The UT Level Committee will have Financial Commissioner Health and Medical Education Department, J&K as chairman and will have 23 other members which include representatives of electronic Media/Print media.
As per the order, the committee will review Case Reporting Forms (CRF), Preliminary Case Investigation Forms (PCIF) and Final Case Investigation Forms (FCIF) for causality assessments, periodically review the data base of AEFI cases. Look for districts not reporting AEFI cases for a long time, conduct field visits & inspections of vaccination sites, cold chain stores, Interviewing AEFI cases/relatives, treating Wors/Staff, Vaccinators, members of District AEFI Committee, if required.
Also to provide technical guidance on policy and implementation of LJT AEFI Surveillance Programme, review AEFI Programme Guidelines/SOPs and establish systems to ensure reporting of quality data, review AEFI Programme Guidelines/SOPs and establish systems to ensure reporting of quality data, conduct periodic evaluation of AEFI surveillance in the UT and suggest processes for greater integration of the private sector in the AEFI programme, including reporting, investigation and response.
The committee will work on strength integration with the UT Pharmacovigilance Programme with partners from Pharmacology Department 0-1 Colleges, ensure meeting of devel AEFI Committee every quarter/once in every month during COVID 19 vaccination or as &when required, support the Media Spokesperson for communication and to ensure minutes of the meeting are recorded and shared with the Government of India.
While as District Level Committee will constitute Chief Medical Officer as Chairman and will have 12 other members.
The District Level Committee will analyze the Case Reporting Forms (CRF) and plan for case investigation of the AEFl as a team, to provide appropriate inputs to the drug authority to decide on temporarily suspending use of the implicated batch of vaccine/diluents/syringe and to assist investigation of AEFI case with technical inputs and visit field for the investigation, if needed
Also to append signatures to the Case Investigation Form (CIFs) based on the findings of the investigations of the AEFI case, to outline the course of action post AEF, to analyze programme information, media reports and other sources of information on serious AEFI and ensure reporting and investigation are of highest strands.
|
